Case report: Successful treatment of non-bullous lichen planus pemphigoides with dupilumab.

Front Med (Lausanne)

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Published: December 2022

Lichen planus pemphigoides (LPP) is a rare autoimmune bullous disease, characterized by the coexistence of lichen planus and subepidermal bullae. However, the minority of LPP patients present with papules rather than vesicles or blisters, which is defined as non-bullous LPP. The diagnosis of LPP relies on manifestations, histopathology, serological assay, and direct immunofluorescence of linear disposition of IgG and/or C3 at the basement membrane zone. Up to now, no standard therapeutic strategies have been proposed for the treatment of LPP. Herein, we describe an uncommon non-bullous LPP patient with widespread papules and erythema, probably induced by vaccination. During hospitalization, he had a poor response to the conventional treatment of topical and systemic corticosteroids, and his condition was finally alleviated by the addition of dupilumab. For LPP patients with a traditional medication failure, or who were not suitable for a higher dose of corticosteroids, a combination with dupilumab could be an alternative option.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800862PMC
http://dx.doi.org/10.3389/fmed.2022.1023458DOI Listing

Publication Analysis

Top Keywords

lichen planus
12
planus pemphigoides
8
lpp patients
8
non-bullous lpp
8
lpp
7
case report
4
report successful
4
successful treatment
4
treatment non-bullous
4
non-bullous lichen
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!